CHINET 2009 surveillance of bacterial resistance in China

Chinese Journal of Infection and Chemotherapy

Volumn 10, Issue 5, 2010, Pages 325-334

  Wang, Fu ^a   Zhu, Demei ^a   Hu, Fupin ^a   Ruan, Feiyi ^a   Ni, Yuxing ^a   Sun, Jingyong ^a   Xu, Yingchun ^a   Zhang, Xiaojiang ^a   Hu, Yunjian ^a   Ai, Xiaoman ^a   Yu, Yunsong ^a   Yang, Qing ^a   Sun, Ziyong ^a   Li, Li ^a   Jia, Bei ^a   Huang, Wenxiang ^a   Zhuo, Chao ^a   Su, Danhong ^a   Wei, Lianhua ^a   Wu, Ling ^a   Zhang, Chaoxia ^a   Ji, Ping ^a   Wang, Chuanqing ^a   Xue, Jianchang ^a   Zhang, Hong ^a   Li, Wanhua ^a   Xu, Yuanhong ^a   Shen, Jilu ^a   Shan, Bin ^a   Du, Yan ^a   more..

^a FUDAN UNIVERSITY   (China)

Author keywords

Bacterial resistance surveillance; Bacterial susceptibility testing; Extended spectrum lactamases; Multi drug resistant bacteria; Pan resistant gram negative bacillus; Vancomycin resistant Enterococcus; methicillin resistant Staphylococcus aureus

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFPROZIL; CEFTRIAXONE; CEFUROXIME; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; FOSFOMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE; RIFAMPICIN; SULPERAZON; SULTAMICILLIN; TEICOPLANIN; VANCOMYCIN;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; CHINA; COAGULASE NEGATIVE STAPHYLOCOCCUS; DISEASE PREDISPOSITION; DISEASE SURVEILLANCE; ENTEROBACTERIACEAE; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GENERAL HOSPITAL; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEALTH PROGRAM; HOSPITAL; INFECTION SENSITIVITY; MENINGITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PEDIATRIC HOSPITAL; PHENOTYPE; STAPHYLOCOCCAL BACTEREMIA;

EID: 77958017939     PISSN: 10097708     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Clinical Laboratory Standard Institute. Performance standards for antimicrobial susceptibility testing [S]. M100-S19, 2009.
2. Clinical Laboratory Standard Institute. Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria [S]. Approved Guideline M45-A, 2006, 26(19).
3. Yang QW, Wang H, Sun HL, et al. Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China [J]. Antimicrob Agents Chemother, 2010, 54(1), 573-577.
4. Wang H, Guo P, Sun HL et al. Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp from Chinese hospitals [J]. Antimicrob Agents Chemother, 2007, 51(11): 4022-4028.
5. Perez F, Hujer AM, Hujer KM et al. Global challenge of multidrug resistant Acinetobacter baumannii [J]. Antimicrob Agents Chemother, 2007, 51(10): 3471-3484.
6. Boucher HW, Talbot G, Bradley JS, et al. Bad bugs, no drugs: No ESKAPE! An update from the IDSA[J]. Clin Infent Dis, 2009, 48(1):1-12.
7. Li J, Nation RL, Milne RW, et al. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria [J]. Intl J Antimicrob Agents, 2005, 25(1):11-25.
8. Elemam A, Rahimian J, Mandell W. Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature [J]. Clin Infent Dis, 2009, 49(2): 271-274.
9. Pachón-Ibáñez ME, Jiménez-Mejías ME, Pichardo C, et al. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem[J]. Antimicrob Agents Chemother, 2004,48(11): 4479-4481.
10. Stein GE, Craig WA. Tigecycline: a critical analysis[J]. Clin Infent Dis, 2006, 43(4): 518-524.
11. Gordon NC, Wareham DW. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline [J]. J Antinicrob Chemother, 2009, 63(4): 775-780.
12. Moland ES, Craft DW, Hong SG, et al. In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecyline-amikacin synergy[J]. Antimicrob Agents Chemother, 2008, 52(8): 2940-2942.
13. Song JY, Kee SY, Hwang IS, et al. In vitro activities of car-bapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbpenem-resistant Acinetobacter baumannii [J]. J Antimicrob Chemother, 2007, 60(2): 317-322.